A review on the use of statins and tocotrienols, individually or in combination for the treatment of osteoporosis

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Skeletal tissue undergoes continuous remodeling which makes it unique among other body tissues. Osteoporosis is a common bone metabolic disorder affecting both men and women. Osteoporosis and its complications mainly osteoporotic fractures, have a high impact on health and economy. Current approved medications are associated with numerous side effects, which limit their use. Identification of a new and safe therapy is mandatory. Statins, also known as HMGCoA reductase inhibitors, are frequently used for the treatment of hypercholesterolemia and for the prevention of morbidity and mortality associated with cardiovascular disease. Statins improved bone health status in intact and ovariectomised rodents following high clinically intolerable oral doses. However, this beneficial effect of statins could not be significantly demonstrated in humans. The reason behind this discrepancy might be due to the safety and bioavailability of the currently used oral statins. Vitamin E, especially the tocotrienols at the dose 60 mg/kg/day provided significant antiosteoporotic effects in different animal models of osteoporosis. The use of the aforementioned dose of tocotrienols was shown to be safe in both humans and animals. Enhancement of bone formation and reduction of bone resorption were achieved more effectively by a combination of tocotrienols and statins than by either treatment when supplemented separately at clinically tolerable doses. Therefore, the adverse effects associated with high statin doses might be avoided with the coadministration of tocotrienols. Moreover, the combination therapy strategy might be useful for patients who are at high risk of osteoporosis, cardiovascular events and hypercholesterolaemia.

Original languageEnglish
Pages (from-to)1579-1590
Number of pages12
JournalCurrent Drug Targets
Volume14
Issue number13
DOIs
Publication statusPublished - 2013

Fingerprint

Tocotrienols
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Osteoporosis
Bone
Hypercholesterolemia
Animals
Therapeutics
Health
Tissue
Bone and Bones
Osteoporotic Fractures
Bone Resorption
Vitamin E
Osteogenesis
Biological Availability
Health Status
Rodentia
Oxidoreductases
Cardiovascular Diseases
Animal Models

Keywords

  • Combination
  • HMGCoA reductase
  • Individaul
  • Mevlonate
  • Osteoporosis
  • Statins
  • Tocotrienols

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Molecular Medicine
  • Drug Discovery
  • Pharmacology
  • Medicine(all)

Cite this

@article{a32993cee194461b9e0fde51f44ef6af,
title = "A review on the use of statins and tocotrienols, individually or in combination for the treatment of osteoporosis",
abstract = "Skeletal tissue undergoes continuous remodeling which makes it unique among other body tissues. Osteoporosis is a common bone metabolic disorder affecting both men and women. Osteoporosis and its complications mainly osteoporotic fractures, have a high impact on health and economy. Current approved medications are associated with numerous side effects, which limit their use. Identification of a new and safe therapy is mandatory. Statins, also known as HMGCoA reductase inhibitors, are frequently used for the treatment of hypercholesterolemia and for the prevention of morbidity and mortality associated with cardiovascular disease. Statins improved bone health status in intact and ovariectomised rodents following high clinically intolerable oral doses. However, this beneficial effect of statins could not be significantly demonstrated in humans. The reason behind this discrepancy might be due to the safety and bioavailability of the currently used oral statins. Vitamin E, especially the tocotrienols at the dose 60 mg/kg/day provided significant antiosteoporotic effects in different animal models of osteoporosis. The use of the aforementioned dose of tocotrienols was shown to be safe in both humans and animals. Enhancement of bone formation and reduction of bone resorption were achieved more effectively by a combination of tocotrienols and statins than by either treatment when supplemented separately at clinically tolerable doses. Therefore, the adverse effects associated with high statin doses might be avoided with the coadministration of tocotrienols. Moreover, the combination therapy strategy might be useful for patients who are at high risk of osteoporosis, cardiovascular events and hypercholesterolaemia.",
keywords = "Combination, HMGCoA reductase, Individaul, Mevlonate, Osteoporosis, Statins, Tocotrienols",
author = "Saif Abdul-Majeed and Norazlina Mohamed and Soelaiman, {Ima Nirwana}",
year = "2013",
doi = "10.2174/13894501113149990193",
language = "English",
volume = "14",
pages = "1579--1590",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "13",

}

TY - JOUR

T1 - A review on the use of statins and tocotrienols, individually or in combination for the treatment of osteoporosis

AU - Abdul-Majeed, Saif

AU - Mohamed, Norazlina

AU - Soelaiman, Ima Nirwana

PY - 2013

Y1 - 2013

N2 - Skeletal tissue undergoes continuous remodeling which makes it unique among other body tissues. Osteoporosis is a common bone metabolic disorder affecting both men and women. Osteoporosis and its complications mainly osteoporotic fractures, have a high impact on health and economy. Current approved medications are associated with numerous side effects, which limit their use. Identification of a new and safe therapy is mandatory. Statins, also known as HMGCoA reductase inhibitors, are frequently used for the treatment of hypercholesterolemia and for the prevention of morbidity and mortality associated with cardiovascular disease. Statins improved bone health status in intact and ovariectomised rodents following high clinically intolerable oral doses. However, this beneficial effect of statins could not be significantly demonstrated in humans. The reason behind this discrepancy might be due to the safety and bioavailability of the currently used oral statins. Vitamin E, especially the tocotrienols at the dose 60 mg/kg/day provided significant antiosteoporotic effects in different animal models of osteoporosis. The use of the aforementioned dose of tocotrienols was shown to be safe in both humans and animals. Enhancement of bone formation and reduction of bone resorption were achieved more effectively by a combination of tocotrienols and statins than by either treatment when supplemented separately at clinically tolerable doses. Therefore, the adverse effects associated with high statin doses might be avoided with the coadministration of tocotrienols. Moreover, the combination therapy strategy might be useful for patients who are at high risk of osteoporosis, cardiovascular events and hypercholesterolaemia.

AB - Skeletal tissue undergoes continuous remodeling which makes it unique among other body tissues. Osteoporosis is a common bone metabolic disorder affecting both men and women. Osteoporosis and its complications mainly osteoporotic fractures, have a high impact on health and economy. Current approved medications are associated with numerous side effects, which limit their use. Identification of a new and safe therapy is mandatory. Statins, also known as HMGCoA reductase inhibitors, are frequently used for the treatment of hypercholesterolemia and for the prevention of morbidity and mortality associated with cardiovascular disease. Statins improved bone health status in intact and ovariectomised rodents following high clinically intolerable oral doses. However, this beneficial effect of statins could not be significantly demonstrated in humans. The reason behind this discrepancy might be due to the safety and bioavailability of the currently used oral statins. Vitamin E, especially the tocotrienols at the dose 60 mg/kg/day provided significant antiosteoporotic effects in different animal models of osteoporosis. The use of the aforementioned dose of tocotrienols was shown to be safe in both humans and animals. Enhancement of bone formation and reduction of bone resorption were achieved more effectively by a combination of tocotrienols and statins than by either treatment when supplemented separately at clinically tolerable doses. Therefore, the adverse effects associated with high statin doses might be avoided with the coadministration of tocotrienols. Moreover, the combination therapy strategy might be useful for patients who are at high risk of osteoporosis, cardiovascular events and hypercholesterolaemia.

KW - Combination

KW - HMGCoA reductase

KW - Individaul

KW - Mevlonate

KW - Osteoporosis

KW - Statins

KW - Tocotrienols

UR - http://www.scopus.com/inward/record.url?scp=84889030592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889030592&partnerID=8YFLogxK

U2 - 10.2174/13894501113149990193

DO - 10.2174/13894501113149990193

M3 - Article

C2 - 23848479

AN - SCOPUS:84889030592

VL - 14

SP - 1579

EP - 1590

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 13

ER -